ZNF48

Summary

ZNF48 (zinc finger protein 48, HGNC:13114) is a protein-coding gene on chromosome 16p11.2, encoding Zinc finger protein 48 (Q96MX3). May be involved in transcriptional regulation.

Enables identical protein binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 197407 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 93 total
• MANE Select transcript: NM_001214909

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13114
Approved symbol	ZNF48
Name	zinc finger protein 48
Location	16p11.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp762K013, FLJ31751, MGC43952
Ensembl gene	ENSG00000180035
Ensembl biotype	protein_coding
Entrez	197407

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000320159, ENST00000495929, ENST00000528032, ENST00000613509, ENST00000622647, ENST00000872220

RefSeq mRNA: 5 — MANE Select: NM_001214909 NM_001214906, NM_001214907, NM_001214909, NM_001324494, NM_152652

CCDS: CCDS10679, CCDS73868

Canonical transcript exons

ENST00000613509 — 3 exons

Exon	Start	End
ENSE00001221414	30397330	30400108
ENSE00001914699	30395420	30395578
ENSE00002190040	30395780	30395873

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 88.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.7967 / max 61.3257, expressed in 1688 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
153654	6.9379	1595
153650	0.9244	481
153649	0.8250	471
153653	0.7185	283
153655	0.3909	214

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	88.82	gold quality
endothelial cell	CL:0000115	87.60	gold quality
ganglionic eminence	UBERON:0004023	87.46	gold quality
middle temporal gyrus	UBERON:0002771	85.46	gold quality
tendon of biceps brachii	UBERON:0008188	84.35	silver quality
pancreatic ductal cell	CL:0002079	83.82	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.53	gold quality
tibialis anterior	UBERON:0001385	82.92	silver quality
prefrontal cortex	UBERON:0000451	81.57	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.70	gold quality
cerebellar vermis	UBERON:0004720	80.44	silver quality
primary visual cortex	UBERON:0002436	80.13	gold quality
epithelial cell of pancreas	CL:0000083	80.01	silver quality
quadriceps femoris	UBERON:0001377	79.82	gold quality
medial globus pallidus	UBERON:0002477	79.81	gold quality
ileal mucosa	UBERON:0000331	79.51	gold quality
frontal cortex	UBERON:0001870	79.42	gold quality
globus pallidus	UBERON:0001875	79.10	gold quality
ventricular zone	UBERON:0003053	78.86	gold quality
granulocyte	CL:0000094	78.81	gold quality
occipital lobe	UBERON:0002021	78.81	gold quality
neocortex	UBERON:0001950	78.80	gold quality
deltoid	UBERON:0001476	78.64	silver quality
vastus lateralis	UBERON:0001379	78.54	gold quality
right frontal lobe	UBERON:0002810	78.23	gold quality
cardiac muscle of right atrium	UBERON:0003379	78.12	gold quality
left ventricle myocardium	UBERON:0006566	78.02	gold quality
Brodmann (1909) area 9	UBERON:0013540	77.74	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	77.51	gold quality
cerebral cortex	UBERON:0000956	77.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.61

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting ZNF48, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-6848-3P	99.64	66.49	885
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-2116-5P	99.32	69.34	1273
HSA-MIR-6843-3P	99.26	66.42	915
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4717-3P	99.06	66.34	1072
HSA-MIR-622	98.99	66.48	1050
HSA-MIR-4272	98.76	68.74	1810
HSA-MIR-6728-3P	98.63	67.63	1534
HSA-MIR-4660	97.79	67.44	1328
HSA-MIR-3189-5P	97.55	66.71	655
HSA-MIR-4676-5P	97.54	65.29	715
HSA-MIR-575	97.54	65.18	718
HSA-MIR-10400-3P	97.29	64.66	597
HSA-MIR-4674	97.29	64.62	597
HSA-MIR-4749-3P	96.40	66.24	798
HSA-MIR-24-1-5P	95.57	65.85	492
HSA-MIR-24-2-5P	95.57	66.16	484
HSA-MIR-3605-3P	82.57	60.78	98

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf646	ENSDARG00000061424
danio_rerio	si:dkey-89b17.4	ENSDARG00000075545
danio_rerio	zgc:66472	ENSDARG00000075916
danio_rerio	si:ch211-148l7.4	ENSDARG00000094469
danio_rerio	znf576.1	ENSDARG00000097819
mus_musculus	Zfp553	ENSMUSG00000045598
rattus_norvegicus	Znf48	ENSRNOG00000017837
drosophila_melanogaster	az2	FBGN0025185
drosophila_melanogaster	CG2129	FBGN0030008
drosophila_melanogaster	CG1602	FBGN0033186
drosophila_melanogaster	indra	FBGN0035213
drosophila_melanogaster	CG30020	FBGN0050020
drosophila_melanogaster	mld	FBGN0263490

Paralogs (36): ZNF302 (ENSG00000089335), ZNF184 (ENSG00000096654), CTCF (ENSG00000102974), ZNF574 (ENSG00000105732), ZBTB24 (ENSG00000112365), ZNF142 (ENSG00000115568), CTCFL (ENSG00000124092), ZNF473 (ENSG00000142528), ZNF827 (ENSG00000151612), ZNF689 (ENSG00000156853), ZNF208 (ENSG00000160321), ZNF91 (ENSG00000167232), ZNF526 (ENSG00000167625), ZNF764 (ENSG00000169951), ZNF747 (ENSG00000169955), ZNF282 (ENSG00000170265), ZNF160 (ENSG00000170949), ZNF497 (ENSG00000174586), ZBTB34 (ENSG00000177125), ZNF771 (ENSG00000179965), ZNF594 (ENSG00000180626), ZBTB37 (ENSG00000185278), ZFP92 (ENSG00000189420), ZNF107 (ENSG00000196247), ZNF729 (ENSG00000196350), ZNF569 (ENSG00000196437), ZNF420 (ENSG00000197050), ZNF785 (ENSG00000197162), ZNF665 (ENSG00000197497), ZNF181 (ENSG00000197841), ZNF347 (ENSG00000197937), ZNF84 (ENSG00000198040), ZBTB48 (ENSG00000204859), ZNF845 (ENSG00000213799), ZNF99 (ENSG00000213973), ZNF688 (ENSG00000229809)

Protein

Protein identifiers

Zinc finger protein 48 — Q96MX3 (reviewed: Q96MX3)

Alternative names: Zinc finger protein 553

All UniProt accessions (3): A0A087WVT1, E9PJ50, Q96MX3

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (5): NP_001201835, NP_001201836, NP_001201838, NP_001311423, NP_689865 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096

UniProt features (41 total): zinc finger region 12, sequence conflict 7, region of interest 6, cross-link 6, compositionally biased region 5, sequence variant 3, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MX3-F1	62.49	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 1, 87, 179, 269, 329, 477, 610

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 75 (showing top): GGAANCGGAANY_UNKNOWN, chr16p11, SCGGAAGY_ELK1_02, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, MTF1_Q4, KRIEG_HYPOXIA_NOT_VIA_KDM3A, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, ATF6_TARGET_GENES, BARX1_TARGET_GENES, DLX6_TARGET_GENES, ELF2_TARGET_GENES, FOXD2_TARGET_GENES, NAB2_TARGET_GENES, SNIP1_TARGET_GENES, TEAD2_TARGET_GENES

GO Biological Process (1): regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (5): DNA binding (GO:0003677), zinc ion binding (GO:0008270), identical protein binding (GO:0042802), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
nucleic acid binding	1
transition metal ion binding	1
protein binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

586 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF48	C8orf33	Q9H7E9	444
ZNF48	KAT8	Q9H7Z6	437
ZNF48	AAMP	Q13685	430
ZNF48	GORASP1	Q9BQQ3	392
ZNF48	ZNF438	Q7Z4V0	367
ZNF48	PLB1	Q6P1J6	338
ZNF48	RWDD1	Q9H446	338
ZNF48	NOL3	O60936	332
ZNF48	ZNF827	Q17R98	323
ZNF48	ZNF428	Q96B54	319
ZNF48	NKAPL	Q5M9Q1	319
ZNF48	NASP	P49321	314
ZNF48	SCARF2	Q96GP6	311
ZNF48	RBM27	Q9P2N5	307
ZNF48	CCDC97	Q96F63	306

IntAct

121 interactions, top by confidence:

A	B	Type	Score
MORF4L2	ZNF48	psi-mi:“MI:0915”(physical association)	0.670
ZNF48	APOBEC3C	psi-mi:“MI:0915”(physical association)	0.670
H1-1	RRP8	psi-mi:“MI:0914”(association)	0.640
PRPF31	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
BYSL	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
EIF3E	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
GOLGA6L9	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
MTUS2	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
ZNF792	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
ZNF48	OSBPL3	psi-mi:“MI:0915”(physical association)	0.560
SF3B4	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
HOOK2	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
CEP55	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
TACC1	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
TRIM41	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
TLE5	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
ZNF48	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
ZNF774	ZNF48	psi-mi:“MI:0915”(physical association)	0.560
ZNF48	FNDC11	psi-mi:“MI:0915”(physical association)	0.560
RBM34	NVL	psi-mi:“MI:0914”(association)	0.530
RRP8	NVL	psi-mi:“MI:0914”(association)	0.530

BioGRID (179): ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-MS), ZNF48 (Affinity Capture-RNA), ZNF48 (Affinity Capture-MS), ZNF48 (Two-hybrid), ZNF48 (Two-hybrid)

ESM2 similar proteins: A1L0T3, A1L4H1, A6QNY1, D3YZF7, O95428, P28698, P30203, P55068, P55106, P59222, P98162, Q04756, Q14767, Q28019, Q28062, Q28256, Q28343, Q28670, Q3U515, Q4G0T1, Q5F378, Q5HZW5, Q61003, Q61361, Q6H9L7, Q6KF10, Q6PGE4, Q6QNF4, Q7TQH7, Q7Z4F1, Q86T13, Q86VR7, Q86VZ4, Q8BV57, Q8BZE1, Q8CB67, Q8VCP9, Q8WTU2, Q91V98, Q96DN2

Diamond homologs: A1L2U9, A2A884, A2ANX9, A7Y7X5, B0X9H6, B0YDH7, B1WAZ8, B1WBU4, E9PW05, E9PZZ1, G5EBU4, O15391, O60315, O62836, O75362, O77459, O95863, P08048, P0CS62, P0CS63, P10925, P15822, P17010, P17012, P20662, P22227, P25490, P28166, P31509, P31629, P36197, P52739, P52746, P56270, P56670, P56671, P60319, P80944, Q00899, Q00900

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 76 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	8	21.6×	6e-08
Viral mRNA Translation	8	21.6×	6e-08
Formation of a pool of free 40S subunits	9	21.4×	2e-08
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	8	21.4×	6e-08
Selenocysteine synthesis	8	20.5×	6e-08
Eukaryotic Translation Termination	8	20.5×	6e-08
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	8	20.0×	6e-08
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	8	20.0×	6e-08

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	8	22.1×	1e-06
negative regulation of translation	6	17.6×	1e-04
rRNA processing	8	16.9×	5e-06
translation	8	12.3×	4e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	90
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2459 predictions. Top by Δscore:

Variant	Effect	Δscore
16:30378697:CTTA:C	acceptor_gain	1.0000
16:30378698:TTA:T	acceptor_gain	1.0000
16:30378699:TA:T	acceptor_gain	1.0000
16:30378701:C:CC	acceptor_gain	1.0000
16:30378705:G:T	acceptor_gain	1.0000
16:30378709:CAG:C	acceptor_gain	1.0000
16:30378710:A:T	acceptor_gain	1.0000
16:30378711:G:C	acceptor_gain	1.0000
16:30378711:G:GC	acceptor_gain	1.0000
16:30379013:CTCA:C	donor_loss	1.0000
16:30379014:TCA:T	donor_loss	1.0000
16:30379016:ACC:A	donor_loss	1.0000
16:30379017:C:CA	donor_loss	1.0000
16:30379179:CTCCA:C	acceptor_gain	1.0000
16:30379180:TCCA:T	acceptor_gain	1.0000
16:30379181:CCA:C	acceptor_gain	1.0000
16:30379181:CCAC:C	acceptor_gain	1.0000
16:30379182:CA:C	acceptor_gain	1.0000
16:30379182:CAC:C	acceptor_gain	1.0000
16:30379184:C:CC	acceptor_gain	1.0000
16:30379912:T:A	donor_gain	1.0000
16:30379930:ACC:A	donor_loss	1.0000
16:30379931:C:CG	donor_loss	1.0000
16:30379945:T:TA	donor_gain	1.0000
16:30380036:C:CT	acceptor_gain	1.0000
16:30380037:A:T	acceptor_gain	1.0000
16:30381123:A:AC	donor_gain	1.0000
16:30381124:C:CC	donor_gain	1.0000
16:30381124:CA:C	donor_gain	1.0000
16:30381387:T:TA	donor_gain	1.0000

AlphaMissense

4009 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:30397611:T:C	F121L	0.999
16:30397613:C:A	F121L	0.999
16:30397613:C:G	F121L	0.999
16:30397674:T:C	C142R	0.999
16:30397695:T:C	F149L	0.999
16:30397696:T:C	F149S	0.999
16:30397697:T:A	F149L	0.999
16:30397697:T:G	F149L	0.999
16:30397851:T:C	F201L	0.999
16:30397852:T:C	F201S	0.999
16:30397853:C:A	F201L	0.999
16:30397853:C:G	F201L	0.999
16:30397935:T:C	F229L	0.999
16:30397936:T:C	F229S	0.999
16:30397937:T:A	F229L	0.999
16:30397937:T:G	F229L	0.999
16:30398100:T:C	F284L	0.999
16:30398102:T:A	F284L	0.999
16:30398102:T:G	F284L	0.999
16:30398184:T:C	F312L	0.999
16:30398185:T:C	F312S	0.999
16:30398186:T:A	F312L	0.999
16:30398186:T:G	F312L	0.999
16:30398247:T:C	C333R	0.999
16:30398268:T:C	F340L	0.999
16:30398269:T:C	F340S	0.999
16:30398270:C:A	F340L	0.999
16:30398270:C:G	F340L	0.999
16:30398607:T:C	C453R	0.999
16:30398628:T:C	F460L	0.999

dbSNP variants (sampled 300 via entrez): RS1000065551 (16:30389604 C>T), RS1000165138 (16:30395177 G>A,T), RS1000206884 (16:30390776 A>G), RS1000239297 (16:30390413 T>C,G), RS1000385193 (16:30377214 CA>C,CAA), RS1000416774 (16:30389189 C>G), RS1000626290 (16:30383346 G>A,T), RS1000665259 (16:30400577 C>A), RS1000670604 (16:30382523 A>C), RS1000866840 (16:30393912 T>A,G), RS1001017529 (16:30387930 A>G), RS1001093791 (16:30394551 C>T), RS1001205929 (16:30396218 T>C), RS1001217853 (16:30396511 G>A,T), RS1001465514 (16:30383435 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST010703_269	Brain morphology (MOSTest)	4.000000e-13
GCST010796_3833	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-09
GCST010796_3834	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement
EFO:0004327	electrocardiography

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	2
Valproic Acid	decreases expression, increases methylation	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
bisphenol A	increases expression	1
benzo(e)pyrene	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Acetaminophen	increases expression	1
Lead	affects expression	1
Methapyrilene	decreases methylation	1
Phthalic Acids	increases methylation	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
Gold Compounds	increases methylation, decreases expression	1
Antirheumatic Agents	decreases expression	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW50	HEK293 eGFP-ZNF48	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer